Exclusive Summary

• Backed by US-FDA GMP certification and approved US registration, enabling immediate high-value distribution in the US and fast-track market entry globally.
• Perfectly addresses the chronic and frequent supply chain shortages of sterile injectables (including Lidocaine) in the US and globally, using stable manufacturing capacity to attract major distributors.
• As a WHO Essential Medicine available in full specifications (1%, 2%, 4%), it meets the rigid demand of over 300 million global surgeries annually, ensuring rapid systematic sales volume.
• Leverages China's manufacturing cost advantages, arming overseas distributors with aggressive pricing capabilities and lucrative margins for hospital tenders and GPO contracts.